Table 2 Disease status prior to lymphodepletion.

From: Intention-to-treat outcomes utilising a stringent event definition in children and young people treated with tisagenlecleucel for r/r ALL through a national access scheme

 

n = 125 infused patients

 

n

%/IQR

BM status

 MRD negative

15

12.0%

 <5%

57

45.6%

 ≥5%

48

38.4%

 Unknown

5

4.0%

BM disease burden

2%

0.09–12%,

  

range 0–100%

CNS status

 CNS1

103

82.4%

 CNS2

3

2.4%

 CNS3

–

–

 Unknown

19

15.2%

 Non-CNS EMD

3*

2.4%

  1. *3 patients with EMD had “stable” finding on MRI/US imaging, 1 patient “reduced” compared with previous. None had signs of progression or activity prior to lymphodepletion.
Back to article page